GALAPAGOS PRESENTED NEW DATA AT ICML 2025 FROM COHORT 3 OF ATALANTA-1 IN RELAPSED/REFRACTORY INDOLENT NHL PATIENTS, DEMONSTRATING HIGH COMPLETE RESPONSE AND MRD NEGATIVITY RATES WITH CAR-T CANDIDATE GLPG5101
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.